4
Changes in Ownership
Aligos Therapeutics, Inc. Filed Acc 0001610717-24-000100
Options or other derivatives
- Chief Medical Officer acquired 157,324 shares (grant or award)
- Chief Medical Officer returned 370,626 shares (to the company)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| McClure Matthew W. Chief Medical Officer | 2024-02-27 | Returned to the company · Stock Option (Right to Buy) | −255,626 | 0 | D | ||
| McClure Matthew W. Chief Medical Officer | 2024-02-27 | Returned to the company · Stock Option (Right to Buy) | −92,000 | 0 | D | ||
| McClure Matthew W. Chief Medical Officer | 2024-02-27 | Returned to the company · Stock Option (Right to Buy) | −23,000 | 0 | D | ||
| McClure Matthew W. Chief Medical Officer | 2024-02-28 | Grant or award · Stock Option (Right to Buy) | +75,183 | 75,183 | D | ||
| McClure Matthew W. Chief Medical Officer | 2024-02-28 | Grant or award · Stock Option (Right to Buy) | +65,713 | 65,713 | D | ||
| McClure Matthew W. Chief Medical Officer | 2024-02-28 | Grant or award · Stock Option (Right to Buy) | +16,428 | 16,428 | D | ||
Loading xslF345X05/form4.xml…